Apotex Secures Canadian License For Loqtorzi From Coherus
The Announcement Follows A Series Of Biosimilars Licensing Deals
After announcing a pivot to innovative oncology treatments from biosimilars, Coherus has granted an exclusive license for its novel biologic cancer therapy Loqtorzi to Apotex in Canada.
